Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells

Abstract

// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Jinle Tang1, Jialu Li1, Xuejun Zhu3, Yuan Yu1, Dan Chen2, Lei Yuan4, Zhenyang Gu4, Xingding Zhang1, 2, 6, Lin Qi2, Zhishu Gong7, Pengjun Jiang3, Juhua Yu3, Huimin Meng1, Gangli An1, Huyong Zheng5, *, Lin Yang1, 2, 6, * 1The Cyrus Tang Hematology Center, Soochow University, Suzhou, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China 2Suzhou Cancer Immunotherapy and Diagnosis Engineering Center, Suzhou, China 3Division of Hematology, Department of Medicine, Jiangsu Provincial Traditional Chinese Medical Hospital, Nanjing, Jiangsu Province, China 4Department of Hematology, Chinese PLA General Hospital, Beijing, China 5Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Key Laboratory of Major Diseases in Children, Ministry of Education, Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing, China 6The Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 7The Medical Group of Zhengzhou First People’s Hospital, Zhengzhou, China *These authors contributed equally to this work Correspondence to: Lin Yang, e-mail: yanglin@suda.edu.cn Huyong Zheng, e-mail: zhenghuyong@bch.com.cn Keywords: immunotoxin, nanobody, VHH, leukemia, target delivery drug Received: November 23, 2015 Accepted: March 28, 2016 Published: April 12, 2016